



FOR IMMEDIATE RELEASE

PCI's Tredegar Site Announces Significant Expansion of Analytical Laboratories at its Center of Excellence for Contained Manufacturing

Philadelphia, USA –March 19, 2018. Global pharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to announce a laboratory expansion at its site in Tredegar, Wales, UK.

The Tredegar facility is PCI's development and manufacturing Center of Excellence with specialist expertise in the processing of highly potent molecules. The site has undergone significant investments over recent years; this latest project ensures analytical capacity and capability to service increasing customer demand.

The investment will see PCI's laboratory increase its analyst headcount by approximately 60 percent and increase its High-Performance Liquid Chromatography (HPLC) capacity in excess of 20 percent, in addition to tripling its capacity for sample receipt. The layout design of the facility incorporates state-of-the-art Lean philosophies and optimized safety, combined with leading ergonomic principles, to deliver enhanced throughput and additional efficiency improvements.

Since launching its contained manufacturing facility utilizing the latest in containment technology at Tredegar, the site has seen significant growth in its global customer base. This latest project will ensure that PCI is able to service both existing and potential new clients, as well as offering a project initiation in terms of analytical transfer within 4-6 weeks.

The site offers a true Center of Excellence for the development and manufacturing of pharmaceutical products in a variety of dosage forms and has over 30 years of experience in the specialist handling of potent molecules. Investment in state-of-the-art contained equipment, combined with the creation of a 'Potent Passport' philosophy to identify the specific handling requirements for every Highly Potent Active Pharmaceutical Ingredient (HPAPI) project, defines PCI as a market leader within this space. Contained technology includes Xcelodose[®] micro-dosing for early stage development drug-in-capsule (DIC), fluid bed granulation and roller compaction for products sensitive to heat and moisture.

Commenting on the expansion, PCI Senior Vice President, International, Richard Yarwood said:

"Expansion of our laboratory services is an important program for the Tredegar site. Speed to market is of



critical importance to our clients. We pride ourselves on continually improving our service for both existing and potential new clients and our analytical service is integral from the early stages of analytical development through to commercial launch and the associated annual stability testing.”

He continued “Among our many key strengths is our ability to on-board projects faster than our competitors. This additional footprint will ensure we are able to continue to offer this speed of project initiation addressing customer need.”

To find out more about PCI please visit www.pciservices.com.

About PCI

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over four decades in the healthcare business. Leading technology and continued investment enables us to address global development needs throughout the product life cycle — from Phase I clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com or follow us on Twitter at [@PCI_Social](https://twitter.com/PCISocial).

Contact

Chantel Richman / Carrie Lowe at BECG
chantel.richman@becg.com / carrie.lowe@becg.com

T: +44 (0)20 3697 0158 / +44 (0)1962 893 913